Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
O'Hare T, Zabriskie MS, Eiring AM, Deininger MW . Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513–526.
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396–409.
Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657–3660.
Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501–1510.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912–8919.
Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O . Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochim Biophys Acta 2013; 1834: 1449–1459.
Kavalerchik E, Goff D, Jamieson CH . Chronic myeloid leukemia stem cells. J Clin Oncol 2008; 26: 2911–2915.
Morrison SJ, Scadden DT . The bone marrow niche for haematopoietic stem cells. Nature 2014; 505: 327–334.
Kohli L, Passegue E . Surviving change: the metabolic journey of hematopoietic stem cells. Trends Cell Biol 2014; 24: 479–487.
Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 2013; 19: 1513–1517.
Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 2013; 121: 1824–1838.
Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 1158–1165.
Liu CC, Leclair P, Yap SQ, Lim CJ . The membrane-proximal KXGFFKR motif of alpha-integrin mediates chemoresistance. Mol Cell Biol 2013; 33: 4334–4345.
Chorzalska A, Salloum I, Shafqat H, Khan S, Marjon P, Treaba D et al. Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. Leukemia 2014; 28: 2165–2177.
Shalapour S, Hof J, Kirschner-Schwabe R, Bastian L, Eckert C, Prada J et al. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica 2011; 96: 1627–1635.
Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D et al. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood 2013; 121: 1814–1818.
Nwajei F, Konopleva M . The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol 2013; 2013: 953982.
Lane SW, Scadden DT, Gilliland DG . The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114: 1150–1157.
Shi Y, Alin K, Goff SP . Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev 1995; 9: 2583–2597.
Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Kocher T et al. Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA 2009; 106: 7414–7419.
Ring C, Ginsberg MH, Haling J, Pendergast AM . Abl-interactor-1 (Abi1) has a role in cardiovascular and placental development and is a binding partner of the alpha4 integrin. Proc Natl Acad Sci USA 2011; 108: 149–154.
Dubielecka PM, Ladwein KI, Xiong X, Migeotte I, Chorzalska A, Anderson KV et al. Essential role for Abi1 in embryonic survival and WAVE2 complex integrity. Proc Natl Acad Sci USA 2011; 108: 7022–7027.
Yang JT, Rayburn H, Hynes RO . Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 1995; 121: 549–560.
Kwee L, Burns DK, Rumberger JM, Norton C, Wolitzky B, Terry R et al. Creation and characterization of E-selectin- and VCAM-1-deficient mice. Ciba Found Symp 1995; 189: 17–28(discussion 28-34, 77-18).
The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cells Biology at Rhode Island Hospital. We wish to acknowledge Rhode Island Foundation grant no. 20133980 (PMD).
The authors declare no conflict of interest.
About this article
Cite this article
Chorzalska, A., Dubielecka, P. New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance. Leukemia Suppl 3, S7–S8 (2014). https://doi.org/10.1038/leusup.2014.4
- integrin alpha 4
- acquired drug resistance
- bone marrow microenvironment